OncoMatch/Clinical Trials/NCT07052253
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Is NCT07052253 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TT-00420 (tinengotinib) and AK104 for hepatocellular carcinoma (hcc).
Treatment: TT-00420 (tinengotinib) · AK104 · AK112 — An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination with TT-00420 Tablet in Patients with Advanced Hepatocellular Carcinoma(HCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE C, BCLC STAGE B (IF UNSUITABLE FOR CURATIVE TOPICAL TREATMENT) (BCLC)
Barcelona Clinic Liver Cancer (BCLC) stage C; or stage B and assessed by the investigator as unsuitable for curative topical treatment
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anti-cancer treatment
No prior systemic anti-cancer treatment for hepatocellular carcinoma
Cannot have received: topical treatment for liver cancer
Received topical treatment for liver cancer within 4 weeks prior to the first administration
Cannot have received: systemic anti-tumor drugs
Received any systemic anti-tumor drugs within 4 weeks prior to the first administration
Cannot have received: other clinical trial drugs
Received other clinical trial drugs within 4 weeks prior to the first administration
Lab requirements
Blood counts
adequate bone marrow function
Liver function
child-pugh liver function score ≤7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07052253 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage BCLC STAGE C or BCLC STAGE B (IF UNSUITABLE FOR CURATIVE TOPICAL TREATMENT) is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify